Answers are grounded in this paper and cite their sources.
Background: Achievement of the best initial response to induction regimen in multiple myeloma is a prognostic factor for disease outcome. The triplet regimenbortezomib, lenalidomide, and dexamethasone, VRd, is the preferred induction regimen in newly diagnosed Multiple Myeloma (MM) due to its favorable impact on overall survival. However, recent studies showed a deeper response and superior progression-free survival with quadruplet regimen, daratumumab-VRd, when compared to VRd. Yet, the quadruplet regimen also comes with additional toxicities. Balancing effi cacy and toxicity in selecting an induction regimen is a challenge due to advanced age and comorbidities in the multiple myeloma population.
No takes yet. Share an insight, caveat, or question.
Keruakous et al. (2021) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: